PURPOSE: The aim of this study was to investigate the effect of Ki67-ZD55-IL-24 with temozolomide (TMZ) against melanoma in mice. METHODS: Seventy-eight mice with subcutaneous injection of A375 cells (2 × 10(6)) into the right flank were randomized to receive phosphate buffered saline (PBS), Ki67-ZD55, Ki67-ZD55-IL-24, TMZ, TMZ + Ki67-ZD55, and TMZ + Ki67-ZD55-IL-24. Six mice were killed in each group 10 days after intervention for detecting IL-24 mRNA and protein expression. The remaining mice were monitored to draw the body weight change curve and tumor growth curve, and killed 30 days after intervention. Tumors were excised and weighted. The morphology of tumor tissues was determined by hematoxylin and eosin (HE) staining, and the apoptosis index and rate of apoptotic cells were determined by TUNEL assay and AnnexinV-FITC/PI double staining, respectively. RESULTS: The Ki67-ZD55-IL-24-treated group generated much more reactive oxygen species than the untreated group. There was no significant difference in IL-24 expression between Ki67-ZD55-IL-24 and TMZ + Ki67-ZD55-IL-24 groups. Immunohistochemical analysis and Western blot revealed that both the Ki67-ZD55 and Ki67-ZD55-IL-24 could significantly reduce the expression of MGMT. Toxicity assessments demonstrated that mice in the three groups that received TMZ exhibited significant body weight loss following treatment. HE staining showed that TMZ + Ki67-ZD55-IL-24 group had much fewer karyokinesis in the tumors, compared with other groups. The apoptosis index of tumor tissues and the rate of apoptotic cells were significantly higher in TMZ + Ki67-ZD55-IL-24 group than in other groups (all P < 0.05). CONCLUSIONS: These findings indicate this novel strategy holds promising potentials for treatment of malignant melanoma.
PURPOSE: The aim of this study was to investigate the effect of Ki67-ZD55-IL-24 with temozolomide (TMZ) against melanoma in mice. METHODS: Seventy-eight mice with subcutaneous injection of A375 cells (2 × 10(6)) into the right flank were randomized to receive phosphate buffered saline (PBS), Ki67-ZD55, Ki67-ZD55-IL-24, TMZ, TMZ + Ki67-ZD55, and TMZ + Ki67-ZD55-IL-24. Six mice were killed in each group 10 days after intervention for detecting IL-24 mRNA and protein expression. The remaining mice were monitored to draw the body weight change curve and tumor growth curve, and killed 30 days after intervention. Tumors were excised and weighted. The morphology of tumor tissues was determined by hematoxylin and eosin (HE) staining, and the apoptosis index and rate of apoptotic cells were determined by TUNEL assay and AnnexinV-FITC/PI double staining, respectively. RESULTS: The Ki67-ZD55-IL-24-treated group generated much more reactive oxygen species than the untreated group. There was no significant difference in IL-24 expression between Ki67-ZD55-IL-24 and TMZ + Ki67-ZD55-IL-24 groups. Immunohistochemical analysis and Western blot revealed that both the Ki67-ZD55 and Ki67-ZD55-IL-24 could significantly reduce the expression of MGMT. Toxicity assessments demonstrated that mice in the three groups that received TMZ exhibited significant body weight loss following treatment. HE staining showed that TMZ + Ki67-ZD55-IL-24 group had much fewer karyokinesis in the tumors, compared with other groups. The apoptosis index of tumor tissues and the rate of apoptotic cells were significantly higher in TMZ + Ki67-ZD55-IL-24 group than in other groups (all P < 0.05). CONCLUSIONS: These findings indicate this novel strategy holds promising potentials for treatment of malignant melanoma.
Authors: Poulam M Patel; Stefan Suciu; Laurent Mortier; Wim H Kruit; Caroline Robert; Dirk Schadendorf; Uwe Trefzer; Cornelis J A Punt; Reinhard Dummer; Neville Davidson; Juergen Becker; Robert Conry; John A Thompson; Wen-Jen Hwu; Kristel Engelen; Sanjiv S Agarwala; Ulrich Keilholz; Alexander M M Eggermont; Alain Spatz Journal: Eur J Cancer Date: 2011-05-18 Impact factor: 9.162
Authors: Christina Quirin; Stanimira Rohmer; Inés Fernández-Ulibarri; Michael Behr; Andrea Hesse; Sarah Engelhardt; Philippe Erbs; Alexander H Enk; Dirk M Nettelbeck Journal: Hum Gene Ther Date: 2011-02-02 Impact factor: 5.695
Authors: C Heise; T Hermiston; L Johnson; G Brooks; A Sampson-Johannes; A Williams; L Hawkins; D Kirn Journal: Nat Med Date: 2000-10 Impact factor: 53.440
Authors: E Galanis; S H Okuno; A G Nascimento; B D Lewis; R A Lee; A M Oliveira; J A Sloan; P Atherton; J H Edmonson; C Erlichman; B Randlev; Q Wang; S Freeman; J Rubin Journal: Gene Ther Date: 2005-03 Impact factor: 5.250
Authors: Sunil Chada; R Bryan Sutton; Suhendan Ekmekcioglu; Julie Ellerhorst; John B Mumm; Wolfgang W Leitner; Heng-Yin Yang; Aysegul A Sahin; Kelly K Hunt; Kerry L Fuson; Nancy Poìndexter; Jack A Roth; Rajagopal Ramesh; Elizabeth A Grimm; Abner M Mhashilkar Journal: Int Immunopharmacol Date: 2004-05 Impact factor: 4.932
Authors: V Chiarion-Sileni; M Guida; L Ridolfi; A Romanini; P Del Bianco; J Pigozzo; S Brugnara; G Colucci; R Ridolfi; G L De Salvo Journal: Br J Cancer Date: 2011-05-24 Impact factor: 7.640
Authors: Dominik E Dorer; Frank Holtrup; Kurt Fellenberg; Johanna K Kaufmann; Sarah Engelhardt; Jörg D Hoheisel; Dirk M Nettelbeck Journal: PLoS One Date: 2011-11-30 Impact factor: 3.240
Authors: Jorge G Gomez-Gutierrez; Jonathan Nitz; Rajesh Sharma; Stephen L Wechman; Eric Riedinger; Elvis Martinez-Jaramillo; Heshan Sam Zhou; Kelly M McMasters Journal: Virology Date: 2015-11-09 Impact factor: 3.616
Authors: Rodolfo Garza-Morales; Roxana Gonzalez-Ramos; Akiko Chiba; Roberto Montes de Oca-Luna; Lacey R McNally; Kelly M McMasters; Jorge G Gomez-Gutierrez Journal: Cancers (Basel) Date: 2018-05-17 Impact factor: 6.639